| Year | Title | Author(s) |
| 2024 |
The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury
Biomedicine & Pharmacotherapy |
Katerelos, M Gleich, K Harley, G Loh, K Oakhill, JS Kemp, BE de Souza, DP Narayana, VK Coughlan, MT Laskowski, A Ling, NXY Murray-Segal, L Brink, R Lee, M Power, DA Mount, PF |
| 2022 |
Blocking AMPK?1 myristoylation enhances AMPK activity and protects mice from high-fat diet-induced obesity and hepatic steatosis
Cell Reports |
Neopane, K Kozlov, N Negoita, F Murray-Segal, L Brink, R Hoque, A Ovens, AJ Tjin, G McAloon, LM Yu, DY Ling, NXY Sanders, MJ Oakhill, JS Scott, JW Steinberg, GR Loh, K Kemp, BE Sakamoto, K Galic, S |
| 2020 |
Genetic loss of AMPK-glycogen binding destabilises AMPK and disrupts metabolism
Molecular Metabolism |
Hoffman, NJ Whitfield, J Janzen, NR Belhaj, MR Galic, S Murray-Segal, L Smiles, WJ Ling, NXY Dite, TA Scott, JW Oakhill, JS Brink, R Kemp, BE Hawley, JA |
| 2015 |
Nuclear factor kappa B-inducing kinase activation as a mechanism of pancreatic beta cell failure in obesity
J. Exp. Med. |
Malle, EK Zammit, NW Walters, SN Koay, YC Wu, JM Tan, BM Villanueva, JE Brink, R Loudovaris, T Cantley, J McAlpine, SR Hesselson, D Grey, ST |